Abstract
Angiogenesis, the formation of new blood vessels is essential for diverse physiological processes such as development, but also for pathological conditions like tumor growth. Most studied in this context are tyrosine kinase signaling pathways such as those involving vascular endothelial growth factor (VEGF). There is however accumulating evidence that more pathways are as essential for angiogenesis. Knockout studies of factors in transforming growth factor β (TGF-β) signaling have for example showed that also this pathway is indispensable for angiogenesis. This review highlights our understanding of TGF-β signaling in vascular development and angiogenesis. In particular, we focus on recent insights into the role of the TGF-β type I receptor ALK1 and co-receptor endoglin in tumor angiogenesis, which provide opportunities for the development of new anti-angiogenesis therapies for treatment of cancer patients.
Keywords: ALK1, angiogenesis, BMP, cancer, Endoglin, Smad, TGF-β, anti-angiogenesis therapy, vascular development, pathological conditions, blood pressure and vascular tone, endothelial cells, tumor growth., tumorigenesis, kinase-domains
Current Pharmaceutical Biotechnology
Title: TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Volume: 12 Issue: 12
Author(s): Laurens A. van Meeteren, Marie-Jose Goumans and Peter ten Dijke
Affiliation:
Keywords: ALK1, angiogenesis, BMP, cancer, Endoglin, Smad, TGF-β, anti-angiogenesis therapy, vascular development, pathological conditions, blood pressure and vascular tone, endothelial cells, tumor growth., tumorigenesis, kinase-domains
Abstract: Angiogenesis, the formation of new blood vessels is essential for diverse physiological processes such as development, but also for pathological conditions like tumor growth. Most studied in this context are tyrosine kinase signaling pathways such as those involving vascular endothelial growth factor (VEGF). There is however accumulating evidence that more pathways are as essential for angiogenesis. Knockout studies of factors in transforming growth factor β (TGF-β) signaling have for example showed that also this pathway is indispensable for angiogenesis. This review highlights our understanding of TGF-β signaling in vascular development and angiogenesis. In particular, we focus on recent insights into the role of the TGF-β type I receptor ALK1 and co-receptor endoglin in tumor angiogenesis, which provide opportunities for the development of new anti-angiogenesis therapies for treatment of cancer patients.
Export Options
About this article
Cite this article as:
A. van Meeteren Laurens, Goumans Marie-Jose and ten Dijke Peter, TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808338
DOI https://dx.doi.org/10.2174/138920111798808338 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Community-Acquired Pneumonia in Children
Recent Patents on Inflammation & Allergy Drug Discovery Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Magnetic Resonance Imaging in the Encephalopathic Term Newborn
Current Pediatric Reviews Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Sonic Hedgehog, the Penis and Erectile Dysfunction: A Review of Sonic Hedgehog Signaling in the Penis
Current Pharmaceutical Design Human Mesenchymal Stem Cells Increases Expression of α-Tubulin and Angiopoietin 1 and 2 in Focal Cerebral Ischemia and Reperfusion
Current Neurovascular Research Molecular Imaging to Monitor Repair of Myocardial Infarction Using Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells
Current Gene Therapy The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Congenital Parenchymal Lesions of the Lung
Current Respiratory Medicine Reviews Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
Current Pharmaceutical Design Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Metalloproteinase-Mediated Shedding of Heparin-Binding Egf-Like Growth Factor and Its Pathophysiological Roles
Protein & Peptide Letters Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Sweet on Hedgehogs: Regulatory Roles of Heparan Sulfate Proteoglycans in Hedgehog-Dependent Cell Proliferation and Differentiation
Current Protein & Peptide Science Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Drugs Targeting Pathophysiology of Intracerebral Hemorrhage: From Animal Models to Clinical Applications
Current Pharmaceutical Design Low-Cost Infertility Management
Current Women`s Health Reviews